Menopause Review, 2021 Şal, Hidayet/0000-0002-3586-6125Introduction: To assess the effect of low-dose combined oestradiol and norethindrone acetate hormone therapy (HT) on serum C-reactive protein (CRP) levels and life quality in natural menopause women.
Servin Gocer +3 more
doaj +2 more sources
HT update: spotlight on estradiol/norethindrone acetate combination therapy
Clinical Interventions in Aging, 2008 Colleen L Casey, Christine A MurrayUniversity of Vermont, Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Burlington, VT, USAAbstract: The goal of postmenopausal hormone therapy is to alleviate the ...
Colleen L Casey, Christine A Murray
doaj +1 more source
Medical management of recurrent endometrioma with long-term norethindrone acetate
International Journal of Women's Health, 2012 Ozgul Muneyyirci-Delale1,2, Jenny Anopa1, Cassandra Charles1, Deepali Mathur1, Rudolph Parris1, Jed B Cutler2, Ghadir Salame1,2, Ovadia Abulafia1,21Department of Obstetrics and Gynecology, SUNY Downstate Medical Center, New York, NY, USA; 2Department of ...
Muneyyirci-Delale O +7 more
doaj +1 more source
Use of Oral Gonadotropin Releasing Hormone Antagonist Combinations for Preoperative Management of Refractory Leiomyoma-Related Heavy Menstrual Bleeding [PDF]
Women's Health ReportsUterine leiomyomas are noncancerous smooth muscle neoplasms that occur in up to 70% of women and the single most common cause of hysterectomy. There is a variety of treatments available for uterine leiomyomas, including medications, uterine artery ...
Danielle A. Aase, Elizabeth A. Stewart
doaj +2 more sources
Safety and efficacy of relugolix combination therapy in symptomatic uterine fibroids [PDF]
Facts, Views & Vision in ObGynBackground: Relugolix-combination therapy (CT) (oestradiol 1 mg and norethindrone acetate 0.5 mg) is a new gonadotropin-releasing hormone antagonist licensed to treat heavy menstrual bleeding (HMB) associated with uterine fibroids; but little real-world ...
Maria Chiara De Angelis +7 more
doaj +2 more sources
Considerations for Menstrual Suppression in Patients With Hematologic Malignancies. [PDF]
PharmacotherapyABSTRACT Patients who menstruate during treatment for hematologic malignancies have a higher risk of heavy vaginal bleeding due to thrombocytopenia caused by malignancy and myelosuppressive chemotherapy. Heavy menstrual bleeding is associated with significant morbidity in this patient population, and menstrual suppression is a standard of supportive ...
Veeravalli S +3 more
europepmc +2 more sources
Fertility and Sterility, 2004 OBJECTIVE: To determine the role of an aromatase inhibitor, letrozole, in the treatment of reproductive-age women with endometriosis and associated chronic pelvic pain. DESIGN: Phase 2, open-label, nonrandomized proof-of-concept study.
Bilgin Gürates, Serdar E Bulun
exaly +1 more source
Retraction Note: Management of uterine leiomyoma and adenomyosis: role of hysteroscopy in diagnosis and norethindrone in the treatment [PDF]
Scientific ReportsAhmed Ali +3 more
doaj +2 more sources
A Comparative Metabolomics Study of the Potential Marker Compounds in Feces from Different Hybrid Offspring of Huainan Pigs [PDF]
AnimalsAs a notable native Chinese genetic population, the Huainan pig has an exceptional meat quality but a low percentage of lean meat and subpar genetic performance.
Yufu Li +8 more
doaj +2 more sources